You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes

http://dx.doi.org/10.1136/ebm.11.3.86

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with type 2 diabetes mellitus, what is the effect of long term fenofibrate therapy on coronary heart disease (CHD) events?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★☆☆

    METHODS

    Embedded ImageDesign

    randomised placebo-controlled trial (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]).

    Embedded ImageAllocation

    concealed.*

    Embedded ImageBlinding

    blinded (clinicians, patients, and outcome assessors).*

    Embedded ImageFollow up period

    median 5 years.

    Embedded ImageSetting

    63 centres in Australia, New Zealand, and Finland.

    Embedded ImagePatients

    9795 patients 50–75 years of age (mean age 62 y, 63% men) who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol concentration 3–6.5 mmol/l, and a total cholesterol/high density lipoprotein (HDL) cholesterol ratio ⩾4 or a triglyceride concentration of 1–5 mmol/l, with no clear indication for lipid modifying therapy. Exclusion criteria were renal impairment, chronic liver disease, symptomatic gallbladder disease, or occurrence of a cardiovascular disease (CVD) event within 3 months …

    View Full Text

    Footnotes

    • ↵* See glossary

    • For correspondence: Professor A Keech, University of Sydney, Sydney, New South Wales, Australia. tony{at}ctc.usyd.edu.au

    • Sources of funding: Laboratoires Fournier SA and National Health and Medical Research Council.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 95a-95a Published Online First: 30 May 2006. doi: 10.1136/ebm.11.3.95a